MiNK Therapeutics, Inc. (INKT) AI Dilution Summary

MiNK Therapeutics reported cash of $8,806,977 at 2026-06-30 against estimated monthly burn of $694,271. It is funding itself through its at-the-market program with B. Riley Securities, Inc., which is authorised to $50,000,000. The most recent capital raised was ATM sales through 2026-06-30.